Pfizer Inc. $PFE Shares Purchased by Swedbank AB

Key Points

• Swedbank AB increased its Pfizer stake 12.9% in Q4 to 5,490,272 shares (about 0.10% of the company), buying an additional 627,384 shares valued at $136.7 million.
• Other large institutions — including Vanguard, Franklin Resources, Neuberger Berman, Ameriprise and AQR — also meaningfully boosted positions, and hedge funds/institutional investors now own about 68.36% of Pfizer.
• Pfizer beat Q1 estimates (EPS $0.75 vs $0.72; revenue $14.45B vs $13.84B), reaffirmed FY2026 guidance, and declared a quarterly dividend of $0.43 (annualized yield ~6.5%).

Swedbank AB increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,490,272 shares of the biopharmaceutical company's stock after buying an additional 627,384 shares during the period. Swedbank AB owned about 0.10% of Pfizer worth $136,708,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Franklin Resources Inc. increased its position in shares of Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after buying an additional 8,108,887 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after buying an additional 7,031,162 shares in the last quarter. Neuberger Berman Group LLC grew its stake in Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after acquiring an additional 6,045,763 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Pfizer by 48.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after acquiring an additional 5,978,927 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in Pfizer by 120.9% during the third quarter. AQR Capital Management LLC now owns 9,505,615 shares of the biopharmaceutical company's stock worth $230,986,000 after acquiring an additional 5,202,884 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 beat on both EPS and revenue; management reaffirmed 2026 guidance and emphasized growth from recently launched and acquired products (Eliquis and others) that offset declines from legacy COVID products. A Look At Pfizer NYSE: PFE Valuation After Q1 2026 Beat And Pipeline Progress
• Positive Sentiment: Oncology pipeline momentum: FDA approval of VEPPANU (first PROTAC degrader for a breast‑cancer subtype) and positive Phase 3 ELREXFIO data boost long‑term growth prospects outside COVID. Pfizer Oncology Advances Raise New Questions For Valuation And Momentum
• Positive Sentiment: Vyndamax patent settlement and favorable legal rulings (including on the COVID vaccine in Europe) improve visibility for post‑2028 revenue, reducing some long‑term tail‑risk. Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View
• Neutral Sentiment: Management reaffirmed FY2026 EPS guidance of $2.80–$3.00 (vs. consensus ~2.97) and revenue range slightly below consensus — guidance is intact but not clearly bullish. Pfizer tops Q1 estimates, maintains guidance
• Negative Sentiment: R&D spend increased, which weighed on GAAP profit (profit fell year‑over‑year despite the beat), signaling near‑term margin pressure as Pfizer invests in pipeline development. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
• Negative Sentiment: Some analysts call the report “mild” — the beat and positives may not satisfy skeptics who worry about longer‑term growth execution and the transition away from pandemic-era revenue. Why Pfizer's 'Mild' First-Quarter Report Likely Won't Satisfy Skeptics

Pfizer Stock Performance

Pfizer stock opened at $26.51 on Thursday. The stock has a fifty day moving average price of $27.16 and a 200 day moving average price of $26.14. Pfizer Inc. has a 52 week low of $21.97 and a 52 week high of $28.75. The firm has a market capitalization of $150.74 billion, a P/E ratio of 20.24 and a beta of 0.35. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.48% and a net margin of 11.83%.The firm's revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.5%. Pfizer's payout ratio is 131.30%.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Guggenheim increased their price target on shares of Pfizer from $35.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Royal Bank Of Canada reaffirmed an "underperform" rating and issued a $25.00 target price on shares of Pfizer in a research note on Monday, April 20th. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a report on Friday, April 10th. Cantor Fitzgerald reissued a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Finally, UBS Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $28.74.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.